Literature DB >> 23188195

Limited pulmonary MPA, a new MPA entity? A rheumatologist's perspective.

Luis F Flores-Suárez1.   

Abstract

Microscopic polyangiitis (MPA) frequently involves the lungs. However, as opposed to granulomatosis with polyangiitis (Wegener's), limited forms are not recognised. In recent years, cases have been reported in which the lungs were affected without other organ manifestations. For years, many have been labelled as idiopathic pulmonary fibrosis (IPF). In this review, support for the existence of a limited form of MPA affecting the lungs as well as questions and discussions concerning the similarities and differences to IPF are offered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188195     DOI: 10.1007/s10157-012-0733-0

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  19 in total

Review 1.  Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis.

Authors:  G A Margaritopoulos; M Romagnoli; V Poletti; N M Siafakas; A U Wells; K M Antoniou
Journal:  Eur Respir Rev       Date:  2012-03-01

2.  Microscopic polyangiitis presenting as a "pulmonary-muscle" syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis?

Authors:  Julius Birnbaum; Sonye Danoff; Frederic B Askin; John H Stone
Journal:  Arthritis Rheum       Date:  2007-06

Review 3.  ANCA: associated lung fibrosis.

Authors:  Hidehiro Yamada
Journal:  Semin Respir Crit Care Med       Date:  2011-06-14       Impact factor: 3.119

4.  Microscopic polyangiitis.

Authors:  Lucy Smyth; Gillian Gaskin; Charles D Pusey
Journal:  Semin Respir Crit Care Med       Date:  2004-10       Impact factor: 3.119

5.  Fibrosing alveolitis predating microscopic polyangiitis.

Authors:  A Becker-Merok; J C Nossent; N Ritland
Journal:  Scand J Rheumatol       Date:  1999       Impact factor: 3.641

6.  Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.

Authors:  L Guillevin; B Durand-Gasselin; R Cevallos; M Gayraud; F Lhote; P Callard; J Amouroux; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  1999-03

Review 7.  Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis.

Authors:  Andreas Günther; Martina Korfei; Poornima Mahavadi; Daniel von der Beck; Clemens Ruppert; Philipp Markart
Journal:  Eur Respir Rev       Date:  2012-06-01

8.  A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients.

Authors:  Tomoko Nozu; Mitsuko Kondo; Kazuo Suzuki; Jun Tamaoki; Atsushi Nagai
Journal:  Respiration       Date:  2008-12-11       Impact factor: 3.580

9.  The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase.

Authors:  P B Gaudin; F B Askin; R J Falk; J C Jennette
Journal:  Am J Clin Pathol       Date:  1995-07       Impact factor: 2.493

10.  ANCA-associated lung fibrosis: analysis of 17 patients.

Authors:  Guillaume Foulon; Philippe Delaval; Dominique Valeyre; Benoît Wallaert; Marie-Pierre Debray; Michel Brauner; Pascale Nicaise; Jacques Cadranel; Vincent Cottin; Abdellatif Tazi; Michel Aubier; Bruno Crestani
Journal:  Respir Med       Date:  2008-07-18       Impact factor: 3.415

View more
  1 in total

Review 1.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.